Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma

NCT05296070 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Marginal Zone Lymphoma

Interventions

DRUG: Loncastuximab tesirine 150 µg/Kg
DRUG: Loncastuximab tesirine 75µg/Kg

Sponsor

University of Miami

Collaborators

[object Object]